Jason Gerberry
Stock Analyst at B of A Securities
(3.59)
# 705
Out of 4,814 analysts
159
Total ratings
53.04%
Success rate
2%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $30.50 | +349.18% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $15.15 | +117.89% | 5 | Mar 20, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $23 → $20 | $13.64 | +46.68% | 13 | Mar 6, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $7.39 | +35.32% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $104.43 | +59.92% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $22.52 | +33.21% | 2 | Jan 9, 2025 | |
| EXEL Exelixis | Downgrades: Neutral | $35 → $39 | $36.06 | +8.15% | 2 | Dec 17, 2024 | |
| BLUE bluebird bio | Downgrades: Neutral | $60 → $10 | $4.15 | +140.96% | 8 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $61.99 | +61.32% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $20.35 | +204.67% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $2.70 | +790.54% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.71 | +322.48% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $28.32 | +140.11% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $18.03 | +10.93% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $24.72 | +25.43% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $0.09 | +11,856.52% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $27.05 | +7.21% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $11.21 | +230.06% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $35.16 | +59.29% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $27.94 | +7.37% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $23.50 | +168.09% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $102.02 | +112.70% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $0.29 | +587.29% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $839.90 | -40.47% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.45 | +520.69% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $11.12 | +124.82% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.32 | +278.79% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $4.60 | +487.60% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.12 | +1,685.71% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.49 | +1,951.28% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $173.00 | -45.09% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $49.23 | +21.89% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $22.15 | +67.08% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $77.98 | +15.41% | 11 | Oct 17, 2019 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $30.50
Upside: +349.18%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $15.15
Upside: +117.89%
Teva Pharmaceutical Industries
Mar 6, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $13.64
Upside: +46.68%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $7.39
Upside: +35.32%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $104.43
Upside: +59.92%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $22.52
Upside: +33.21%
Exelixis
Dec 17, 2024
Downgrades: Neutral
Price Target: $35 → $39
Current: $36.06
Upside: +8.15%
bluebird bio
Nov 15, 2024
Downgrades: Neutral
Price Target: $60 → $10
Current: $4.15
Upside: +140.96%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $61.99
Upside: +61.32%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $20.35
Upside: +204.67%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $2.70
Upside: +790.54%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.71
Upside: +322.48%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $28.32
Upside: +140.11%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $18.03
Upside: +10.93%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $24.72
Upside: +25.43%
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $0.09
Upside: +11,856.52%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $27.05
Upside: +7.21%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $11.21
Upside: +230.06%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $35.16
Upside: +59.29%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $27.94
Upside: +7.37%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $23.50
Upside: +168.09%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $102.02
Upside: +112.70%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $0.29
Upside: +587.29%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $839.90
Upside: -40.47%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.45
Upside: +520.69%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $11.12
Upside: +124.82%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.32
Upside: +278.79%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $4.60
Upside: +487.60%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.12
Upside: +1,685.71%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.49
Upside: +1,951.28%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $173.00
Upside: -45.09%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $49.23
Upside: +21.89%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $22.15
Upside: +67.08%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $77.98
Upside: +15.41%